Linezolid Exerts Greater Bacterial Clearance but No Modification of Host Lung Gene Expression Profiling: A Mouse MRSA Pneumonia Model by Chen, Jiwang et al.
Illinois State University
ISU ReD: Research and eData
Faculty Publications – Biological Sciences Biological Sciences
6-1-2013
Linezolid Exerts Greater Bacterial Clearance but
No Modification of Host Lung Gene Expression
Profiling: A Mouse MRSA Pneumonia Model
Jiwang Chen
University of Illinois at Chicago
Gang Feng
Northwestern University Biomedical Informatics Center
Yang Song
Illinois State University, Normal
Juliane B. Wardenburg
University of Chicago
Simon Lin
Northwestern University Biomedical Informatics Center
See next page for additional authors
Follow this and additional works at: http://ir.library.illinoisstate.edu/fpbiosci
Part of the Biology Commons
This Article is brought to you for free and open access by the Biological Sciences at ISU ReD: Research and eData. It has been accepted for inclusion in
Faculty Publications – Biological Sciences by an authorized administrator of ISU ReD: Research and eData. For more information, please contact
ISUReD@ilstu.edu.
Recommended Citation
Chen, Jiwang; Feng, Gang; Song, Yang; Wardenburg, Juliane B.; Lin, Simon; Inoshima, Ichiro; Otto, Michael; and Wunderink,
Richard G., "Linezolid Exerts Greater Bacterial Clearance but No Modification of Host Lung Gene Expression Profiling: A Mouse
MRSA Pneumonia Model" (2013). Faculty Publications – Biological Sciences. Paper 6.
http://ir.library.illinoisstate.edu/fpbiosci/6
Authors
Jiwang Chen, Gang Feng, Yang Song, Juliane B. Wardenburg, Simon Lin, Ichiro Inoshima, Michael Otto, and
Richard G. Wunderink
This article is available at ISU ReD: Research and eData: http://ir.library.illinoisstate.edu/fpbiosci/6
Linezolid Exerts Greater Bacterial Clearance but No
Modification of Host Lung Gene Expression Profiling: A
Mouse MRSA Pneumonia Model
Jiwang Chen1,2*, Gang Feng3, Yang Song4, Juliane B. Wardenburg5, Simon Lin3,6, Ichiro Inoshima5,
Michael Otto7, Richard G. Wunderink1
1 Department of Medicine, Northwestern University, Chicago, Illinois, United States of America, 2 Section of Pulmonary, Critical Care Medicine, Allergy and
Sleep, University of Illinois at Chicago, Chicago, Illinois, United States of America, 3 Northwestern University Biomedical Informatics Center, Chicago, Illinois,
United States of America, 4 Microbiology Group, School of Biological Sciences, Illinois State University, Normal, Illinois, United States of America, 5 Department
of Pediatrics, University of Chicago, Chicago, Illinois, United States of America, 6 Biomedical Informatics Research Center, Marshfield Clinic Research
Foundation, Marshfield, Wisconsin, United States of America, 7 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of
America
Abstract
Background: Linezolid (LZD) is beneficial to patients with MRSA pneumonia, but whether and how LZD influences
global host lung immune responses at the mRNA level during MRSA-mediated pneumonia is still unknown.
Methods: A lethal mouse model of MRSA pneumonia mediated by USA300 was employed to study the influence of
LZD on survival, while the sublethal mouse model was used to examine the effect of LZD on bacterial clearance and
lung gene expression during MRSA pneumonia. LZD (100mg/kg/day, IP) was given to C57Bl6 mice for three days.
On Day 1 and Day 3 post infection, bronchoalveolar lavage fluid (BALF) protein concentration and levels of cytokines
including IL6, TNFα, IL1β, Interferon-γ and IL17 were measured. In the sublethal model, left lungs were used to
determine bacterial clearance and right lungs for whole-genome transcriptional profiling of lung immune responses.
Results: LZD therapy significantly improved survival and bacterial clearance. It also significantly decreased BALF
protein concentration and levels of cytokines including IL6, IL1β, Interferon-γ and IL17. No significant gene
expression changes in the mouse lungs were associated with LZD therapy.
Conclusion: LZD is beneficial to MRSA pneumonia, but it does not modulate host lung immune responses at the
transcriptional level.
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Introduction
Community associated methicillin-resistant Staphylococcus
aureus (CA-MRSA) is an emerging threat to human health
throughout the world. Its epidemic spread and high mortality in
healthy individuals have raised alarm in the biomedical
community. In the USA, CA-MRSA infections are almost
entirely attributed to a pandemic and highly virulent strain,
USA300 [1,2]. CA-MRSA is the most predominant isolates in
patients with noscomial pneumonia [3]. CA-MRSA pneumonia
is characterized by a dramatic inflammatory response in the
lungs, resulting in airway neutrophil influx, loss of alveolar
structure, severe pulmonary edema, hemorrhage,
intrapulmonary bacterial proliferation and high mortality rates
[4,5].
Currently the American Thoracic Society and the Infectious
Diseases Society of the America recommend vancomycin
(VAN) or linezolid (LZD) as first-line agents for treatment of
MRSA pneumonia [6,7]. Mechanistically, LZD selectively binds
to the 50S ribosomal subunit, resulting in inhibition of bacterial
protein synthesis [8]. Through this mechanism, LZD decreases
in vitro production of exotoxins, including Panton Valentine
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Leukocidin (PVL), hemolysins, and enterotoxins. In addition,
exotoxin release leads to a corresponding increase in induction
of tumor necrosis factor, which can be also suppressed with
LZD [9-11]. Using a murine model of pneumonia, Akinnusi et
al. (2011) reported that LZD and VAN have comparable effects
in modulating the expression of metalloproteinases (MMPs) in
bronchoalveolar lavage fluid (BALF) and in regulating
neutrophil activation [12]. They concluded that LZD exhibits a
minimal modulatory effect on innate immunity in the animal
model of MRSA pneumonia. All of these studies were
conducted either via in vitro cell culture models or BALF
characterization in a mouse model of MRSA pneumonia.
Whether LZD modulates host lung immune responses at the
mRNA level during MRSA pneumonia is still unknown.
Previously, a rat necrotizing pneumonia model was used to
study transcription of 84 genes mediating the early
inflammatory response in the lung [5]. These genes include
only inflammatory cytokines, chemokines and their receptors.
In this study, we hypothesized that LZD regulates host-
bacteria interactions by modulating the gene expression profile
in the lung during the MRSA pneumonia. Here we determined
whether and how MRSA modulates host lung immune
responses by genome-wide transcriptional profiling during
pneumonia. In addition, we examined the corresponding effects
of LZD on survival, lung bacterial clearance and acute lung
injury.
Materials and Methods
Bacterial Preparation for Inoculation
USA300 CA-MRSA wild-type LAC strain [13,14] was used in
this study. To prepare an inoculum for animals, a frozen stock
of S. aureus was incubated onto a tryptic soy agar plate at
37°C overnight. A single colony was put into 3 ml tryptic soy
broth (TSB) and incubated overnight in a shaker set at 250 rpm
and 37°C. One milliliter of overnight culture was then grown in
100 ml TSB solution until OD660 was approximately 0.5. Fifty
milliliter of bacteria were then centrifuged at 6000 g for 15 min
at 4°C, washed in sterilized phosphate-buffered solution (PBS)
and resuspended in a certain volume of PBS solution. In the
sublethal model for bacterial clearance and gene expression
profiling assays, the volume of PBS for bacterial resuspension
is 1.5 ml, resulting in an estimated concentration of 1x108 CFU
per 30 µl volume. In the lethal model, the PBS volume was 750
µl, resulting in an estimated concentration of 3~4 x108 CFU per
30 µl volume. After bacterial resuspension, the solution was
immediately used for animal inoculation. All inocula were then
quantified by plating serial dilutions in PBS on tryptic soy agar
and counting colonies after overnight incubation at 37°C. In this
study, the lethal model was used to study how LZD is beneficial
to survival of mice after MRSA pneumonia. Since very few
mice survive > 48 hrs in the lethal model without LZD therapy
[13], the sublethal model was used for bacterial clearance and
gene expression profiling assays.
Animals and Procedures
All animal experiments and procedures were approved by
the Institutional Animal Care and Use Committee in
Northwestern University. The lung infection procedure
described previously [13,14] was followed. Briefly, C57Bl6 male
mice (7 weeks old, Charles River) were anesthetized before
inoculation of 30 µl of USA300 CA-MRSA strain LAC
suspension via the left nare. Animals were held upright for one
minute post-inoculation and then placed into a cage in supine
position for recovery. All animals were provided with food and
water ad libitum. A small number of animal that succumbed
within the first six hours post infection (< 1%) were excluded in
the subsequent data analysis.
Mice were divided into two groups: placebo (PBS) and LAC.
Each group included two subgroups: no LZD treatment and
LZD treatment. Mice were treated with PBS or LZD starting at 6
hours post inoculation, prior to the peak expression of
proinflammatory cytokines or chemokines. LZD was
administered by intraperitoneal injection (I.P), 100 mg/kg/day
for three days. The LZD concentration and treatment time
selected in our model were based on previous studies [15-17]
in order to achieve success against MRSA with minimum
inhibitory concentration (MIC) as high as 2 to 4 μg/ml.
In our established mouse model of MRSA pneumonia,
severely ill mice that show signs of ruffled fur, markedly
decreased activity, surface temperature < 23°C, diminished
righting reflex and decreased respiratory rate are euthanized.
The mice are observed continuously within the first hour after
MRSA inoculation, and then checked once per six hours for up
to three days. In the lethal model, all the surviving mice after
one week were euthanized.
Lung Bacterial Clearance Assay
In the sublethal model, lungs were harvested after the mice
were euthanized and homogenized in 1 ml sterilized PBS.
Serial dilutions (1:10, 1:100) were prepared in PBS and plated
on tryptic soy agar plates. After 24-hr incubation of the plates,
bacterial colonies were counted and the number of colony
forming units (CFU) per ml lung homogenate was calculated.
Bronchoalveolar Lavage Fluid (BALF) Protein
Concentration and Cytokine Measurement
BALF was performed by instilling 1 ml of cold Hank’s Salt
solution (HBSS, Invitrogen, Grand Island, NY) via tracheal
cannula, as previously described [18]. After centrifuge at 600 g
for 10 min, the supernatant was harvested for protein
concentration measurement by Pierce® BCA protein assay kit
(Thermo Scientific Inc, Rockford, IL).
The Bio-plexProTM mouse cytokine TH17 panel A kit
(M60-00007NY, Bio-Rad Inc) was used to measure IL1β, IL-6,
IL-17A, IFN-γ and TNF-α levels in BALF with 6 replications per
group.
Histology Preparation
A 20-gauge angiocath was sutured into the mouse trachea.
The lungs were inflated with 0.8 ml 4% paraformaldehyde
(PFA) and fixed in a 15 ml tube with the same concentration of
PFA solution overnight at 4°C. The fixed lungs were
paraffinized and 5-μm sections were stained with hematoxylin/
eosin.
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Microarray Data and Functional Analysis
RNA expression analysis was performed by the Illumina
MouseRef-8 BeadChip (Illumina, San Diego, CA), which
provides coverage of approximately 25,700 genes and
expressed sequence tags. Four independent mouse lung
tissue samples at Day 1 and Day 3 post MRSA infection were
randomly selected from each group and used for RNA isolation
with RNeasy plus mini kit (Qiagen, Valencia, CA). RNA quality
was checked by Agilent Bioanalyzer (Santa Clara, CA) and
labeled by a commercial kit (TargetAmp 1-Round Aminoallyl-
aRNA Ki; Epicentre, Madison, WI, USA). The labeled RNA was
then hybridized to the Illumina MouseRef-8 BeadChip. Raw
signal intensities of each probe were obtained by data analysis
software (Beadstudio; Illumina) and imported to the Lumi
package of Bioconductor for data transformation and
normalization [19-21]. “Absent/Present” call detection was
performed based on detected p value (p < 0.01). 15,490 out of
25,697 probes were considered valid signals.
Differentially expressed genes were identified by means of
an Analysis of Variance (ANOVA) model with empirical
Bayesian variance estimation [22]. The false discovery rate
(FDR) was adopted to reduce false positives in multiple
comparisons. Stringent criteria (fold change ≥ 1.5 up or down,
P < 0.01, FDR < 0.05) were used to filter significantly
differentially expressed genes. Two-dimensional hierarchical
clustering was applied to these filtered probes to generate a
global overview of the gene expression map (heat map).
Gene Ontology enrichment analysis of the significantly
differentially expressed genes was performed by
GeneAnswers, a Bioconductorpackage, based on
hypergeometric test [23-25]. Microarray data was deposited in
the Gene Expression Omnibus database with accession
number GSE36587 and GSE46071 (GEO database, http://
www.ncbi.nlm.nih.gov/geo/).
Reverse Transcription and Real-time PCR Validation
Two microgram of purified RNA was reverse transcribed to
single-strand cDNA using Taqman RNA reverse transcription
kit (cat. #N8080234, Applied Biosystems Inc [ABI]). Real-time
PCR was performed on an ABI 7900HT machine. Specific
Taqman quantitative real-time PCR assays were ordered from
ABI (specific assay IDs available upon request). The relative
mRNA expression levels were normalized to the expression of
a housekeeping gene, hexose-6-phosphate dehydrogenase
(G6PDH), and determined by calculating the ΔΔCt value, as
detailed in the manufacturer’s guidelines.
Statistical Analysis
P-values for survival data were calculated using the Gehan-
Breslow-Wilcoxon test, with a Wilcoxon rank-sum test for
bacterial clearance data analysis. For analysis of BALF protein
concentration and real-time PCR data, two-tailed Student t-
tests were used for comparisons between two groups. One
way analysis of variance (ANOVA) and pairwise t-test with
Bonferroni-adjustment were used for comparison of over two
groups. Results are displayed with mean ± SEM (standard
error of the mean) for at least three independent experiments.
P < 0.05 was considered statistically significant. All statistical
analysis was performed on GraphPad Prism 5.1 (GraphPad
Software, La Jolla, CA).
Results
(1) LZD Significantly Improves Survival and Lung
Bacterial Clearance in MRSA-mediated Pneumonia
In our lethal model, without LZD treatment, survival rates of
LAC group at 24, 48 and 72 hrs post infection were 62.0 ±
9.0%, 24.8 ± 7.9% and 16.4 ± 2.0%, respectively. With LZD
therapy, survival rates of LAC group at 24, 48 and 72 hrs post
infection were 98.0 ± 2.0%, 91.7 ± 1.2% and 91.7 ± 1.2%,
respectively (Figure 1A). All mice in the PBS or PBS+LZD
groups survived. This clearly demonstrated that LZD
significantly improved survival in the lethal mouse model of
MRSA-mediated pneumonia (p < 0.0001).
In the sublethal mouse model, no deaths occurred in any
groups (data not shown). We checked bacterial number in left
lungs (right lungs were used for gene expression assay) at Day
1 and Day 3 post infection. The data were shown in Figure 1B.
Comparing bacterial numbers between LZD and no LZD-
treated group, LZD significantly improved bacterial clearance at
both Day 1 post infection ([8.65 ± 3.68] x106 CFU vs [1.38 ±
0.086] x106 CFU, p = 0.0013), and at Day 3 post infection
(1148 ± 509 CFU vs 287 ± 83 CFU, p = 0.039). In the group
without LZD treatment, the bacterial burden in the lungs
significantly decreased at Day 3 compared to Day 1 post
MRSA infection (p = 0.0013).
(2) LZD Significantly Attenuated MRSA-mediated Acute
Lung Injury (ALI) Revealed by Lung Histology
Hematoxylin/eosin (HE) staining of lung tissues is shown in
Figure 2. Compared to PBS group, more inflammation with
pulmonary edema, multifocal bacterial aggregates, and lung
structure destruction was seen in the lungs at Day 1 post
MRSA infection. With LZD treatment, no abscesses formed,
less lung edema occurred, and fewer inflammatory cells were
observed compared to no LZD treatment. At Day 3 post MRSA
infection, no multifocal bacterial aggregates could be found,
although the inflammatory infiltrates were still seen in the lung
alveolar space.
(3) LZD Significantly Decreased BALF Protein
Concentrations and Cytokine Levels during MRSA
Pneumonia
BALF protein concentrations dramatically increased in the
LAC group, compared to the control group (PBS inoculated) (p
< 0.001, Figure 3). LZD therapy significantly decreased BALF
protein concentration in the LAC group at day 1 (3178.0 ±
418.4 µg/ml vs 1670.0 ± 98.8 µg/ml, p = 0.008) (Figure 3). It did
not significantly change BALF protein concentration in control
group (319.0 ± 46.2 vs 371.4 ± 41.8 µg/ml, p = 0.43). In the
MRSA infected group, BALF protein concentration significantly
decreased at Day 3 compared to Day 1 (3178.0 ± 418.4 µg/ml
vs 890.3 ± 127.5 µg/ml, p < 0.001).
Our cytokine data (Figure 4) showed LZD significantly
decreases IL1β, IL6, Interferon-γ and IL17 in LAC+LZD group,
Linezolid in a Mouse MRSA Pneumonia Model
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Figure 1.  Survival and lung bacterial clearance data with Linezolid and no Linezolid therapy in MRSA mediated
pneumonia.  A) Survival data after 24 hrs, 48 hrs and 72 hrs post MRSA lung infections in a mouse lethal model of MRSA
pneumonia (38 mice were used in LAC+LZD group and 39 mice in LAC+PBS group). p < 0.0001 calculated by a Gehan-Breslow-
Wilcoxon test). B) Bacterial clearance data at Day 1 and Day 3 post MRSA infection in a mouse sublethal model of MRSA
pneumonia. Twelve mice from three experiments were used in each group. P-values were calculated by a Wilcoxon rank-sum test.
doi: 10.1371/journal.pone.0067994.g001
Linezolid in a Mouse MRSA Pneumonia Model
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compared to LAC group. No significant difference was
demonstrated for any cytokine measured between the PBS and
PBS+LZD groups. In addition, no statistically significant
difference in TNFα levels between the LAC and LAC+LZD
groups (p = 0.38) was demonstrated.
(4) Genome-wide Lung Gene Expression Profiles
during MRSA Pneumonia
Genome-wide lung gene expression profiles of the four
groups of mice (PBS, PBS+LZD, LAC and LAC+LZD) at Day 1
and Day 3 post MRSA lung infections were first examined and
the heatmap is demonstrated in Figure 5A. Four biological
replicates in each group showed highly consistent patterns.
A remarkable difference was demonstrated (Figure 5A)
between PBS and LAC groups at either Day 1 or Day 3 post
MRSA infection. Compared to PBS group, 538 and 1046 genes
were significantly modulated (fold change ≥ 1.5 or ≤ -1.5) in
lungs at Day 1 and Day 3 after MRSA infection, respectively.
Of the 538 differentially expressed genes at Day 1, 261
(48.5%) were up-regulated and 277 (51.5%) were down-
regulated; of the 1046 differentially expressed genes at Day 3,
602 (57.6%) were up-regulated and 444 (42.4%) were down-
regulated. Table 1 lists 33 transcripts, selected according to
their fold changes and functions, up-regulated or down-
regulated at Day 1 or Day 3 post MRSA infection, compared to
PBS group. All the up-regulated and down-regulated genes
were listed in the Tables S1 and S2, respectively. Assignment
of the significantly altered genes into the biological-process GO
category (Figure 5B) revealed genes controlling innate immune
response, inflammatory response, response to wounding,
bacterium and cytokine stimulus, cell differentiation and
migration, apoptosis, cellular nitrogen compound metabolic
process, system development and vasculature development
are significantly modulated by MRSA infection. In each
biological process, transcriptions of more genes were
significantly modified in the lungs at Day 3, compared to Day 1.
(5) LZD Did Not Modulate Lung Gene Expression
Profiling during MRSA Pneumonia
Using the stringent criteria mentioned above (fold change ≥
1.5 up or down, P < 0.01, FDR < 0.05) to filter significantly
differentially expressed genes, we did not identify any genes
whose expression levels were significantly different between
the PBS and PBS+LZD groups or between the LAC and LAC
+LZD at Day 1 or Day 3 post MRSA infection (Figure 5A).
(6)Validation of Gene Expression Changes by Real-time
PCR
Nine genes were randomly selected from Table 1 for
verification by real-time PCR using the Taqman gene
expression assays. LCN2, SAA3, CXCL9, ORM1, Serpina3f
were significantly up-regulated and EPAS1, ESM1, Pon1,
Catalase were significantly down-regulated in lungs at Day 1
after MRSA infection, compared to the PBS group (Figure 6).
Figure 2.  Lung hematoxylin and eosin (HE) staining images.  The images in the first row are the representative groups without
LZD therapy, and the images in the second row are the representative groups with LZD therapy. Magnification time, x20. Compared
to the PBS control group, more inflammation with pulmonary edema, multifocal bacterial aggregates, and lung structure destruction
was seen in the lungs at Day 1 post MRSA infection. With LZD treatment, no abscesses were formed, less lung edema and fewer
inflammatory cells were observed compared to without LZD treatment. At Day 3 post MRSA infection, no multifocal bacterial
aggregates could be found. However, the inflammatory infiltrates were still seen in the lung alveolar space.
doi: 10.1371/journal.pone.0067994.g002
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No significant difference was seen between the LAC and LAC
+LZD groups or between the PBS and PBS+LZD groups in all
the genes tested (Figure 6). All real-time PCR data is
consistent with cDNA microarray data.
Discussion
In this study, we provide evidence showing that LZD
improves survival in a mouse model of lethal MRSA
pneumonia. Furthermore, in a corresponding sublethal model,
LZD therapy was associated with significantly improved
bacterial clearance, attenuated MRSA – mediated ALI, and
decreased concentrations of BALF protein and cytokines such
as IL1β, IL6, IFN-γ and IL17. However, these beneficial effects
of LZD in MRSA pneumonia do not accompany with significant
alterations in host lung transcriptional profile according to our
microarray and real-time PCR data (Figures 5-6). This
indicates that LZD may specifically target on modulating
metabolism of MRSA and efficiently eliminate bacteria in lungs,
but not exert adverse effects on the host lung tissues during
MRSA pneumonia. This is the first study to show that LZD did
not have an effect on genome-wide host lung innate immunity
at the mRNA level. This novel finding is consistent with the
previous findings reported by Akinnusi et al (2011), who
showed that LZD exhibits a minimal modulatory effect on
protein levels of IL-6 and MCP-5 in a murine model of MRSA-
pneumonia [12]. However, Garcia-Roca et al (2006)
demonstrated that LZD significantly suppressed the synthesis
of the cytokines (IL6, TNFα, IL-1ra and IL-1β) in human
peripheral blood mononuclear cells [26]. It is possible that LZD
exerts different effects on cytokine production in in vitro cell
culture models compared to animal models.
LZD decreased protein concentration and cytokine levels in
BALF (Figures 3-4), which we attribute to greater bacterial
clearance (Figure 1B), and thus lower cytokine levels were
produced in the LZD-treated group compared to controls
(Figure 4). In addition, the lung histological data showed that
LZD significantly attenuated MRSA-mediated ALI (Figure 2).
These findings further confirm that efficient elimination of
MRSA from the lungs by LZD decreases the risk of pulmonary
edema and acute lung injury.
To our knowledge, this study was the first to show the
genome-wide lung gene expression profile changes at Day 1
and Day 3 post MRSA infection. Previously it was shown that
inflammatory and blood coagulation components dominated
the early response to MRSA in the lungs or airways [5,27]. Our
microarray data not only confirmed inflammatory and blood
components were significantly modulated by MRSA infection,
but also revealed more transcriptional events during MRSA
pneumonia. These events were listed in Figure 5B. Several
major transcriptional events were highlighted here: 1)
Inflammatory response was activated. Chemokine (C-C motif)
ligand 3 (Ccl3), Ccl4, Ccl7, chemokine (C-X-C motif) ligand 9
(Cxcl9), Cxcl16, serum amyloid A3 (Saa3), orosomucoid 1
(Orm1) were up-regulated (Table 1). Ccl and Cxcl family
members have chemoattractant activity and can elicit
Figure 3.  BALF protein concentration at Day 1 and Day 3 post MRSA lung infections.  Values are the mean ± SEM (standard
error of the mean) of three independent experiments (n = 12 in each group).
doi: 10.1371/journal.pone.0067994.g003
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Figure 4.  Interferon-γ, IL17, IL6, IL1β and TNFα levels in BALF samples at Day 1 post MRSA infections.  Values are the
mean ± SEM (standard error of the mean) of three independent experiments. There is no statistically significant difference in TNFα
levels between the LAC and LAC+LZD groups (p = 0.38).
doi: 10.1371/journal.pone.0067994.g004
Linezolid in a Mouse MRSA Pneumonia Model
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Figure 5.  Genome-wide gene expression profiles in lungs at Day 1 and Day 3 post MRSA infection.  A) Heat map of eight
groups, with four replications per group. Each row represents one sample, and each column represents one gene. Fold change ≥
1.5 up or down, P < 0.01, FDR < 0.05); B) Functional group concept-gene analysis for the comparison between LAC (Day 1) and
PBS (Day 1) and between LAC (Day 3) and PBS (Day 3). The figure shows how many genes are involved in selected relevant
biological pathways and which functions are significantly up-regulated or down-regulated between the LAC and PBS groups at Day
1 or Day 3 post MRSA infection. The background color for each cell is proportional to the hypergeometric test p value. The more
saturated the color is, the smaller the p-value.
doi: 10.1371/journal.pone.0067994.g005
Linezolid in a Mouse MRSA Pneumonia Model
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Table 1. Genes showing significantly different expression levels at Day 1 and Day 3 after MRSA lung infections as compared
to a PBS control group.
Symbol Description Fold Change (DAY 1) Fold Change (DAY 3) Entrez ID
Inflammatory response    
Ccl3 chemokine (C-C motif) ligand 3 25.12 6.11 20302
Ccl4 chemokine (C-C motif) ligand 4 37.6 11.45 20303
Ccl7 chemokine (C-C motif) ligand 7 10.5 4.07 20306
Cxcl9 chemokine (C-X-C motif) ligand9 25.77 22.43 17329
Il1rn interleukin 1 receptor antagonist 12.8 3.98 16181
Orm1 orosomucoid 1 29.03 5.72 18405
Saa3 serum amyloid A 3 28.67 55.2 20210
Innate defense response    
Serpina3f serine (or cysteine) peptidaseinhibitor, clade A, member 3f 11.42 5.62 20717
Serpina3g serine (or cysteine) peptidaseinhibitor, clade A, member 3g 6.69 7.1 20715
Ido1 indoleamine 2,3-dioxygenase 1 10.73 3.62 15930
Lcn2 lipocalin 2 8.13 7.54 16819
GDF15 growth differentiation factor 15 6.01 unavailable 23886
Socs3 suppressor of cytokine signaling3 5.28 2.02 12702
Response to cytokine and reactive oxygen species    
Mmp9 matrix metallopeptidase 9 3.13 2.14 17395
Prdx5 peroxiredoxin 5 2.78 2.21 54683
Cyp2a5 cytochrome P450, family 2,subfamily a, polypeptide 5 -5.56 -7.25 13087
Ephx1 epoxide hydrolase 1,microsomal -3.82 -2.78 13849
Pon1 paraoxonase 1 -3.81 -3.63 18979
Response to wounding    
F10 coagulation factor X 7.04 3.55 14058
Regulation of apoptosis    
Hmox1 heme oxygenase (decycling) 1 3.92 3.05 15368
Casp4 caspase 4 3.45 2.73 12363
Bid BH3 interacting domain deathagonist 1.99 1.93 12122
Bcl3 B cell leukemia/lymphoma 3 1.98 unavailable 12051
Sod2 superoxide dismutase 2,mitochondrial 2.36 unavailable 20656
Cat Catalase -2.44 -1.94 12359
Ednrb endothelin receptor type B -3.23 -1.92 13618
Nox4 NADPH oxidase 4 -2.48 unavailable 50490
Cadm1 cell adhesion molecule 1 -3.28 unavailable 54725
System Development    
Timp1 tissue inhibitor ofmetalloproteinase 1 13.66 5.48 21857
Junb Jun-B oncogene 5.5 1.88 16477
Egr1 early growth response 1 2.38 unavailable 13653
ESM1 endothelial cell-specificmolecule 1 -2.41 -3.37 71690
EPAS1 endothelial PAS domain protein1 -2.34 -4.59 13819
The genes listed in this table have been selected according to the degree of expression difference (fold changes) and functions.
Linezolid in a Mouse MRSA Pneumonia Model
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Figure 6.  Quantitative real-time PCR confirmation of five up-regulated genes that were up-regulated during MRSA
pneumonia (LCN2, CXCL9, Orm1, Saa3, Serpina3f) and four that were down-regulated (ESM1, EPAS1, Pon1,
Catalase).  There was no statistically significant difference between the PBS and PBS+LZD or between the LAC and LAC+LZD
groups.
doi: 10.1371/journal.pone.0067994.g006
Linezolid in a Mouse MRSA Pneumonia Model
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neutrophil recruitment to enhance bacterial clearance [28,29];
2) Innate defense response was also activated. Serpina3,
LCN2, Socs3, Ido1, GDF15 were significantly up-regulated.
These proteins were reported to have an established or
potential role in the innate defense against infections. For
example, Ido1 has anti-microbial activity in a variety of
infectious diseases [28], and LCN2 has been reported to be as
a bacteriostatic protein for protection of airways against
infection by E. coli [30]; 3) Components response to cytokines
and reactive oxygen species were significantly modulated.
These components included MMP9, Prdx5, Cyp2a5, Pon1 and
Ephx1. They may play a protective role in regulation of cellular
levels of cytokines and ROS, which are dramatically increased
at the early stage of MRSA pneumonia. For example, Pon1
functions as an antioxidant [31] and Ephx1 plays an important
role in the detoxification of electrophiles and oxidative stress
[32]. Down-regulation of Ephx1 and Pon1 may ensure a certain
amount of hydrogen peroxide, a potent antimicrobial agent, is
present during pathogen infection; 4) Apoptosis-regulating
proteins were significantly modulated. Hmox1, casp4, Bid,
Bcl3, Sod2 were up-regulated and catalase, NOX4, Cadm1,
Ednrb were down-regulated; 5) System development pathways
were also significantly modified. Timp1, Junb, Egr1 were up-
regulated and Esm1, Epas1 were down-regulated by MRSA
infections. Esm1 and Epas1 have been shown to contribute to
vascular angiogenesis [33-35]. Down-regulation of these
components during MRSA pneumonia may dampen
endothelium integrity. In general, endothelium integrity was
considered as a “natural anticoagulant” [36]. Disruption of
endothelium integrity can cause blood coagulation. This may
explain why coagulation factor X (F10) was up-regulated during
MRSA pneumonia.
There are a few limitations of this study. First, considering
high mortality in the subgroup without LZD treatment (Figure
1A), only a sublethal mouse model of MRSA pneumonia (1 x
108 CFU MRSA/mouse) was used to study the effect of LZD on
host lung gene expression patterns. We have not tested
whether gene expression patterns are affected by different
MRSA inoculum. Second, we have tested the global host lung
gene expression patterns only at Day 1 and Day 3 post MRSA
infection. A substantial effect on host lung gene expression
patterns during the first few hours after LZD therapy may
therefore be missed. Third, the response of host cells may be
affected by LZD in the same way as bacteria. LZD inhibits
bacterial growth at the translational level and not at the
transcriptional level [7]. It is possible that transcription in the
host cells is not affected by LZD but translational levels are,
similar to bacteria. Alternatively, LZD may have no effect on
host innate immune cells. In this case, the benefit of LZD for
MRSA pneumonia is solely greater antibiotic effect without
immunomodulatory effects. In addition, it is possible that LZD
affects transcriptional or translational events in the blood but
not in the alveolar space. Therefore, in future studies, the use
of lethal doses of MRSA given within the first few hours after
LZD therapy and the analysis of protein levels in the lungs and
blood are warranted.
In summary, our data show that LZD significantly improves
survival, bacterial clearance and attenuates BALF protein
concentration and cytokine levels. Lung cDNA microarray data
show that LZD does not modulate lung gene expression
profiles in our sublethal mouse model of MRSA pneumonia. To
our knowledge, this study is the first report of genome-wide
lung gene expression profiles during MRSA pneumonia.
Description of global lung gene expression profiles is important
to understand how murine lung host defense responds to
MRSA pneumonia.
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